Table 2.
Cytotoxicity and antiviral activity of CHLA and PUG against different virus infectionsa
|
Virus |
Cell type |
Compounds |
CC50(μM)b |
Antiviral effect |
|
|---|---|---|---|---|---|
| EC50(μM)c | SId | ||||
| HCMV |
HEL |
CHLA |
306.32 ± 7.00 |
25.50 ± 1.51 |
12.01 |
| |
|
PUG |
299.32 ± 9.14 |
16.76 ± 0.88 |
17.86 |
| HCV |
Huh-7.5 |
CHLA |
237.61 ± 4.53 |
12.16 ± 2.56 |
19.54 |
| |
|
PUG |
222.61 ± 3.41 |
16.72 ± 2.55 |
13.31 |
| DENV-2 |
Vero |
CHLA |
159.63 ± 7.46 |
13.11 ± 0.72 |
12.18 |
| |
|
PUG |
151.44 ± 9.31 |
7.86 ± 0.40 |
19.27 |
| MV |
CHO-SLAM |
CHLA |
351.83 ± 4.54 |
34.42 ± 4.35 |
10.22 |
| |
|
PUG |
283.76 ± 11.54 |
25.49 ± 2.94 |
11.13 |
| RSV |
HEp-2 |
CHLA |
244.17 ± 17.40 |
0.38 ± 0.05 |
642.55 |
| |
|
PUG |
264.83 ± 23.72 |
0.54 ± 0.04 |
490.43 |
| VSV |
A549 |
CHLA |
316.87 ± 9.01 |
61.28 ± 5.50 |
5.17 |
| |
|
PUG |
318.84 ± 4.99 |
36.98 ± 4.59 |
8.62 |
| ADV-5 |
A549 |
CHLA |
316.87 ± 9.01 |
198.14 ± 14.07 |
1.60 |
| PUG | 318.84 ± 4.99 | 196.67 ± 20.05 | 1.62 | ||
a Values shown are means obtained from three independent experiments with each treatment performed in triplicate.
b Cytotoxic effects were evaluated by XTT assay to determine the concentration of 50% cellular cytotoxicity (CC50) of the tested compounds.
c Antiviral effects were evaluated by infection analysis to determine the effective concentration that achieved 50% inhibition (EC50) against the specific virus examined.
d SI, selectivity index. SI = CC50/EC50.